Bioxytran (BIXT) EPS (Basic) Growth (1y) (2012 - 2026)
Bioxytran (BIXT) EPS (Basic) Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | -16.29% |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | -1,458.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.93% |
| Dec 31, 2025 | -4.76% |
| Sep 30, 2025 | -2.34% |
| Jun 30, 2025 | 110.65% |
| Mar 31, 2025 | -332.29% |
| Dec 31, 2024 | 37.70% |
| Sep 30, 2024 | 62.44% |
| Jun 30, 2024 | 66.67% |
| Mar 31, 2024 | 46.79% |
| Dec 31, 2023 | -15.82% |
| Sep 30, 2023 | -373.52% |
| Jun 30, 2023 | -96.52% |
| Mar 31, 2023 | 19.52% |
| Dec 31, 2022 | 23.03% |
| Sep 30, 2022 | 59.64% |
| Jun 30, 2022 | 34.06% |
| Mar 31, 2022 | 49.19% |
| Dec 31, 2021 | -13.42% |
| Sep 30, 2021 | -107.85% |
| Jun 30, 2021 | 9.36% |